Gerald Reaven, MD

Publication Details

  • Familial factors in the antihypertensive response to lisinopril AMERICAN JOURNAL OF HYPERTENSION Hollenberg, N. K., Anzalone, D. A., Falkner, B., Fisher, N. D., Hopkins, P. N., Hsueh, W., Hutchinson, H., Krauss, R. M., Price, D. A., Raskin, P., Reaven, G. M. 2001; 14 (3): 218-223

    Abstract:

    Although it is widely recognized that there are familial elements in the pathogenesis of hypertension, remarkably little is known about the influence of family history on response to specific antihypertensive agents.This study was designed to address that issue by comparing the depressor response to lisinopril in a dose range of 10 to 40 mg in 74 patients enrolled as sibling pairs. Because all patients were treated with lisinopril, ambulatory blood pressure monitoring (ABPM), an objective measure not influenced by the investigators, was used to assess the primary blood pressure (BP) outcome variable.Diastolic BP was highly correlated between sibling pairs at baseline (r = 0.476; P < .03) and on treatment (r = 0.524; P = .0021). Ethnicity/race had a striking influence on lisinopril dose and response rate. Among African American patients, 23 of 28 reached the top dose of 40 mg/day, whereas only 14 of 36 Caucasian patients reached that dose level. Among Caucasians, 92% responded, and only 48% of African Americans. Responders were characterized by being younger and heavier, having significantly lower microalbuminuria at baseline, higher baseline renal plasma flow (RPF), and higher urinary kallikrein.Among Caucasians, the presence of a hypertensive sibling predicts a striking therapeutic response to angiotensin converting enzyme inhibition.

    View details for Web of Science ID 000167285000005

    View details for PubMedID 11281232

Stanford Medicine Resources:

Footer Links: